Amneal Pharmaceuticals NASDAQ: AMRX reported second-quarter 2026 revenue of $796 million, up 10% from a year earlier, as growth in its affordable medicines and specialty businesses offset a decline at its AvKARE distribution unit. The company raised its full-year revenue, adjusted EBITDA and adjusted earnings-per-share outlook, citing broad-based demand, new product launches and favorable product mix.Adjusted EBITDA rose 12% to $206 million, while adjusted diluted earnings per share increased 20% to $0.30. ...

Amneal Pharmaceuticals (NasdaqGS:AMRX) Q2 2026 Earnings call July 30, 2026 08:30 AM ET Company ParticipantsTony DiMeo - Head of Investor RelationsChirag Patel - Co-CEO and PresidentChintu Patel - Co-CEOTasos Konidaris - EVP and CFOConference Call ParticipantsGlen Santangelo - AnalystNone - AnalystDavid Amsellem - AnalystAsh Verma - AnalystMatt Dellatorre - AnalystOperatorGood morning, and welcome to the Amneal Pharmaceuticals second quarter 2026 earnings call. I will now turn the call over to Amneal's Head ...

Amneal Pharmaceuticals (NasdaqGS:AMRX) Q2 2026 Earnings call July 30, 2026 08:30 AM ET Company ParticipantsTony DiMeo - Head of Investor RelationsChirag Patel - Co-CEO and PresidentChintu Patel - Co-CEOTasos Konidaris - EVP and CFOConference Call ParticipantsGlen Santangelo - AnalystNone - AnalystDavid Amsellem - AnalystAsh Verma - AnalystMatt Dellatorre - AnalystOperatorGood morning, and welcome to the Amneal Pharmaceuticals second quarter 2026 earnings call. I will now turn the call over to Amneal's Head ...

Amneal Pharmaceuticals (NasdaqGS:AMRX) Q2 2026 Earnings call July 30, 2026 08:30 AM ET Speaker0Good morning, and welcome to the Amneal Pharmaceuticals second quarter 2026 earnings call. I will now turn the call over to Amneal's Head of Investor Relations, Anthony DiMeo.Speaker1Good morning, and thank you for joining Amneal Pharmaceuticals second quarter 2026 earnings call. Today, we issued a press release reporting Q2 results. The earnings press release and presentation are available on the IR page of amnea ...

Amneal Pharmaceuticals Q2 2026 Earnings Call July 30, 2026 Cautionary statement on forward looking statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management's intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions o ...

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +25.00%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $0.17 per share when it actually produced earnings of $0.27, delivering a surprise of +58.82%.Over the last four ...

Exhibit 99.1 AMNEAL REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS – Q2 2026 Net Revenue of $796 million; GAAP Net Income of $58 million; Diluted Income per Share of $0.18 – – Adjusted EBITDA of $206 million; Adjusted Diluted EPS of $0.30 – – Raising 2026 Full Year Guidance – – Successful Debt Repricing in July Reduces Interest Cost – BRIDGEWATER, NJ, July 30, 2026 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced its results for the second quarter ended June 30, 2026. ...

– Q2 2026 Net Revenue of $796 million; GAAP Net Income of $58 million; Diluted Income per Share of $0.18 –– Adjusted EBITDA of $206 million; Adjusted Diluted EPS of $0.30 –– Raising 2026 Full Year Guidance –– Successful Debt Repricing in July Reduces Interest Cost – BRIDGEWATER, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the second quarter ended June 30, 2026. “Amneal delivered strong, broad-based performanc ...